Latest Blueprint Medicines Stories
CAMBRIDGE, Mass., April 8, 2015 /PRNewswire/ -- Blueprint Medicines today announced it will present new preclinical data on its drug candidate BLU-285 in gastrointestinal stromal tumors (GIST), as
- On track to file IND for BLU-554 and initiate clinical studies by mid-2015 - CAMBRIDGE, Mass., March 16, 2015 /PRNewswire/ -- Blueprint Medicines today announced publication of the discovery
- Collaboration combines Blueprint Medicines' kinase-focused drug discovery platform with Alexion's experience developing and commercializing therapies for severe and life-threatening disorders -
CAMBRIDGE, Mass., Feb.
CAMBRIDGE, Mass., Jan.
SAN FRANCISCO, Dec.
- Builds on Company's novel discovery of several kinase fusion genes in cancer - CAMBRIDGE, Mass., Nov.
-Proceeds to support continued advancement of highly selective kinase inhibitors to genomically defined cancers, including first-in-class FGFR4 and KIT Exon 17 inhibitors- CAMBRIDGE, Mass.,
--Genomic Data in Study Published in Nature Communications Suggests New Treatment Strategies for These Hard to Treat Women's Reproductive Cancers-- BALTIMORE and CAMBRIDGE, Mass., Sept.
- Findings and research approach published in Nature Communications - CAMBRIDGE, Mass., Sept.
- Growing in low tufty patches.